James Luccarelli

James Luccarelli

Auto-generated profile, based on publicly available information

James Luccarelli

Department of Psychiatry Harvard Medical School Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ELElizaveta S. Leshchiner
Elizaveta S. Leshchiner
APAndrey Parkhitko
Andrey Parkhitko
GBGregory H. Bird
Gregory H. Bird
JLJames Luccarelli
James Luccarelli
JBJoseph Bellairs
Joseph Bellairs
LWLoren D. Walensky
Loren D. Walensky
Activating mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) underlie the pathogenesis and chemoresistance of ∼30% of all human tumors, yet the development of high-affinity inhibitors that target the broad range of KRAS mutants remains a formidable challenge. Here, we report the development and validation of stabilized alpha helices of son of sevenless 1 (SAH-SOS1) as prototype therapeutics that directly inhibit wild-type and mutant forms of KRAS. SAH-SOS1 peptides bound in a sequence-specific manner to KRAS and its mutants, and dose-responsively blocked nucleotide association. Importantly, this functional binding activity correlated with SAH-SOS1 cytotoxicity in cancer cells expressing wild-type or mutant forms of KRAS. The mechanism of action of SAH-SOS1 peptides was demonstrated by sequence-specific down-regulation of the ERK-MAP kinase phosphosignaling cascade in KRAS-driven cancer cells and in a Drosophila melanogaster model of Ras85DV12 activation. These studies provide evidence for the potential utility of SAH-SOS1 peptides in neutralizing oncogenic KRAS in human cancer.

23 November 2010 in Journal of Chemical Theory and Computation
Verified
Journal Article
Closed access
JLJames Luccarelli
James Luccarelli
JMJulien Michel
Julien Michel
JTJulian Tirado-Rives
Julian Tirado-Rives
WJWilliam L. Jorgensen
William L. Jorgensen

23 September 2009 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
YSYvonne Schmitz
Yvonne Schmitz
JLJames Luccarelli
James Luccarelli
MKMinji Kim
Minji Kim
MWMi Wang
Mi Wang
DSDavid Sulzer
David Sulzer
Dopamine-releasing neurons of the substantia nigra pars compacta produce an extraordinarily dense and expansive plexus of innervation in the striatum converging with glutamatergic corticostriatal and thalamostriatal axon terminals at dendritic spines of medium spiny neurons. Here, we investigated whether glutamatergic signaling promotes arborization and growth of dopaminergic axons. In postnatal ventral midbrain cultures, dopaminergic axons rapidly responded to glutamate stimulation with accelerated growth and growth cone splitting when NMDA and AMPA/kainate receptors were activated. In contrast, when AMPA/kainate receptors were selectively activated, axon growth rate was decreased. To address whether this switch in axonal growth response was mediated by distinct calcium signals, we used calcium imaging. Combined NMDA and AMPA/kainate receptor activation elicited calcium signals in axonal growth cones that were mediated by calcium influx through L-type voltage-gated calcium channels and ryanodine receptor-induced calcium release from intracellular stores. AMPA/kainate receptor activation alone elicited calcium signals that were solely attributable to calcium influx through L-type calcium channels. We found that inhibitors of calcium/calmodulin-dependent protein kinases prevented the NMDA receptor-dependent axonal growth acceleration, whereas AMPA/kainate-induced axonal growth decrease was blocked by inhibitors of calcineurin and by increased cAMP levels. Our data suggest that the balance between NMDA and AMPA/kainate receptor activation regulates the axonal arborization pattern of dopamine axons through the activation of competing calcium-dependent signaling pathways. Understanding the mechanisms of dopaminergic axonal arborization is essential to the development of treatments that aim to restore dopaminergic innervation in Parkinson's disease.

1 March 2018 in Molecular Cell
Verified
Journal Article
Closed access
SESilvia Escudero
Silvia Escudero
EZElma Zaganjor
Elma Zaganjor
SLSusan Lee
Susan Lee
CMChristopher P. Mill
Christopher P. Mill
AMAnn M. Morgan
Ann M. Morgan
LWLoren D. Walensky
Loren D. Walensky

9 May 2016 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
SLSusan Lee
Susan Lee
TWThomas E Wales
Thomas E Wales
SESilvia Escudero
Silvia Escudero
DCDaniel T Cohen
Daniel T Cohen
JLJames Luccarelli
James Luccarelli
LWLoren D Walensky
Loren D Walensky
MCL-1 is an antiapoptotic BCL-2 family protein that has emerged as a major pathogenic factor in human cancer. Like BCL-2, MCL-1 bears a surface groove whose function is to sequester the BH3 killer domains of proapoptotic BCL-2 family members, a mechanism harnessed by cancer cells to establish formidable apoptotic blockades. Although drugging the BH3-binding groove has been achieved for BCL-2, translating this approach to MCL-1 has been challenging. Here, we report an alternative mechanism for MCL-1 inhibition by small-molecule covalent modification of C286 at a new interaction site distant from the BH3-binding groove. Our structure–function analyses revealed that the BH3 binding capacity of MCL-1 and its suppression of BAX are impaired by molecular engagement, a phenomenon recapitulated by C286W mutagenic mimicry in vitro and in mouse cells. Thus, we characterize an allosteric mechanism for disrupting the antiapoptotic BH3 binding activity of MCL-1, informing a new strategy for disarming MCL-1 in cancer.

1 December 2020 in The Journal of ECT
Verified
Journal Article
Closed access
JLJames Luccarelli
James Luccarelli
MHMichael E. Henry
Michael E. Henry
TMThomas H. Jr McCoy
Thomas H. Jr McCoy
Objectives: Electroconvulsive therapy (ECT) is an effective treatment of depression and other psychiatric conditions. There are few comprehensive data on how many patients receive ECT in the United States or about the demographics of ECT recipients. This study characterizes the demographics of those receiving ECT and how these demographics may have changed with time. Methods: Freedom of information requests for all data from record keeping inception to January 2019 were sent to the Department of Health or equivalent agency of states that mandate reporting of ECT. Information on demographics and the number of treating facilities was extracted. Results: Data on 62,602 patients receiving treatment in 3 states (California, Illinois, Vermont) were obtained. Overall, 62.3% were women. Fewer than 1% of patients treated were younger than 18 years, whereas 30.3% were 65 years or older. White patients received a disproportionate proportion of treatments, with all other races underrepresented. The total number of facilities offering ECT in the 3 states declined over the study period. Conclusions: Recipients of ECT are more likely to be female, more likely to be elderly, and more likely to be white than the average person in their state.